Oncology Brothers: Practice-Changing Cancer Discussions
Treatment Algorithm of Late Relapsed/Refractory Multiple Myeloma (RRMM)
· 24 min
Notas del episodio
In this episode of the Oncology Brothers podcast, we dived deep into the complexities of late relapse refractory multiple myeloma treatment. Joined by Maximilian Merz, MD, a myeloma specialist from the Memorial Sloan Kettering Cancer Center, the discussion covered the evolving treatment landscape, including the use of CAR-T cell therapies, bispecific antibodies, and the importance of assessing BCMA expression.
Key topics included:
The current treatment algorithms for late relapse refractory multiple myeloma
The significance of antigen expression in guiding treatment decisions
The role of bispecific antibodies like teclistamab and talquetamab
Managing side effects and improving patient quality of life
The importance of collaboration between community hematologists and tertiary care centers
Join us as we explored the latest advancements in myeloma treatment and the critical role of patient education and support in navigating this challenging disease. Don't forget to check out our previous episodes on newly diagnosed multiple myeloma and early relapse refractory disease!
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o
Follow us on social media:
X/Twitter: https://x.com/oncbrothers
Instagram: https://www.instagram.com/oncbrothers
Website: https://oncbrothers.com/
Subscribe for more insights and updates on oncology treatments!
#MultipleMyeloma, #CART, #BispecificAntibody, #RelapsedMyeloma, #OncologyBrothers
Web: infoaj7.podbean.com
